Exelixis Bolsters Pipeline in Deal with India's Aurigene

Exelixis, based in Alameda, California, inked a collaboration, option and license deal with India’s Aurigene Discovery Technologies Ltd. Aurigene focuses on oncology and inflammatory diseases. Exelixis is working to build its pipeline behind its flagship product Cabometyx (cabozantinib), and this deal will give it access to up to six Aurigene programs.